Eytan M. Stein, MD: Enasidenib Shows “Encouraging” Efficacy in IDH2-Mutated AML
Treatment with the IDH2 inhibitor enasidenib was well-tolerated and led to an "impressive" response rate in patients with relapsed/refractory IDH2-mutated acute myeloid leukemia. Dr....
Jae Hong Park, MD: Improving Outcomes, Minimizing Toxicity With CAR T-Cell Therapy in B-Cell...
Dr. Park reviews two studies identifying characteristics that can improve durability of outcome, without increasing toxicity, in patients with B-cell acute lymphocytic leukemia.
Frederick Locke, MD: CAR T-Cell Therapy in Relapsed/Refractory NHL
Based on results of the ZUMA-1 trial, axicabtagene ciloleucel was submitted to the FDA earlier this year for patients with chemotherapy-refractory, aggressive non-Hodgkin lymphomas....
Mathias Rummel, MD, PhD: Bendamustine-Rituximab “StiL” Beats R-CHOP for Indolent Lymphomas
Ten-year results from the randomized, phase III StiL trial show that bendamustine plus rituximab leads to longer progression-free survival than R-CHOP in patients with...
Saar Gill, MD: Combining CAR T-Cell Therapy With Ibrutinib in CLL Patients
Adding ibrutinib to treatment with CAR T-cell therapy was feasible, led to deeper remissions, and reduced the severity of cytokine release syndrome in patients...
Aaron Gerds, MD: Glasdegib and New Directions in Myelofibrosis Treatment
Dr. Gerds discusses results from an ongoing trial of glasdegib, a novel hedgehog inhibitor, in patients with heavily pretreated myelofibrosis and significant disease burden.
Nicholas J. Short, MD: Inotuzumab Plus Lower-Intensity Chemotherapy Safe, Effective in Older Patients with...
Dr. Short shares results from a “proof-of-concept” study of the combination of inotuzumab ozogamicin and mini-hyper-CVD chemotherapy in older patients with newly diagnosed acute...
Jeff P. Sharman, MD: Ublituximab Plus Ibrutinib Improves Response Rate in High-Risk CLL
The novel anti-CD20 monoclonal antibody ublituximab (when added to ibrutinib) yielded superior response rates than ibrutinib alone in patients with high-risk chronic lymphocytic leukemia....
Ruben Mesa, MD: Momelotinib Non-Inferior to Ruxolitinib in Myelofibrosis
Dr. Mesa reviews data from the SIMPLIFY 1 trial, which compared the novel JAK1/2 inhibitor momelotinib with ruxolintinib in patients with JAK inhibitor–naïve MF,...
Richard Stone, MD: New FLT3 Inhibitor Crenolanib Shows Promise in FLT3-Mutated AML
The FLT3 inhibitor crenolanib, when added to standard induction chemotherapy, was associated with high rates of minimal residual disease negativity in patients with FLT3-mutated...
Current Issue
September 2017, Volume 3, Issue 11
This issue features a look at efforts to include individuals with intellectual and developmental disabilities in clinical research, our new "How I Treat In Brief" section, and more.
